Clinical trials: SARS-COV2 Virus
COVID-19 Pandemic
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18…
- Trial name
- COVID-19 (NCT05238649)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg, Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg, SARS-Cov-2 Vaccine Inactivated
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
This is a 2-Stage, Phase III, randomized, active-controlled, observer-blind, parallel-group, multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03…
- Trial name
- NCT05007951
- Testing
- GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose), ChAdOx1-S not less than 2.5 × 10^8 infectious units
- Where
- 38 sites in New Zealand, Philippines and 4 more
- Volunteers
- 4,036 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
COVID-19
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
- Trial name
- NCT05313022
- Testing
- ZR-202-CoV
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
COVID
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
This is a phase 1b randomized, double-blind, placebo-controlled study in adult subjects with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04397796
- Testing
- BM-Allo.MSC
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
COVID-19
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.
- Trial name
- NCT04655625
- Testing
- Group A (AG0302-COVID19), Group B (AG0302-COVID19)
- Where
- 8 sites in Japan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Covid19
Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19)
Breath analysis is the evaluation of exhaled air of humans. It aims to get information about the clinical status of a human being by monitoring its volatile organic compounds (VOCs) in exhaled air.
- Trial name
- NCT04556318
- Testing
- Ion Mobility Spectrometry (IMS)
- Where
- 2 sites in Germany
- Volunteers
- 396 people
- Sponsor
- B. Braun Melsungen AG
Covid-19, SARS-CoV-2
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.
- Conditions
- Covid-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04683224
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
COVID-19, SARS-CoV-2
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.
- Trial name
- VICTORIA (NCT05057897)
- Testing
- AZD1222
- Where
- 4 sites in Thailand, Ukraine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
SARS-CoV-2 Infection, COVID19
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised.
- Trial name
- NCT04895982
- Testing
- BNT162b2
- Where
- 29 sites in United States, Brazil and 2 more
- Volunteers
- 124 people
- Sponsor
- BioNTech SE
COVID-19
Assessing Performance of the Testing Done Simple Covid 19 Antigen Test
This study will measure the sensitivity and specificity of the Testing Done Simple severe acute respiratory syndrome (SARS) CoV-2 antigen test in subjects with suspected Covid-19 that present throughout several urgent care…
- Trial name
- NCT05610449
- Testing
- Testing Done Simple SARS CoV-2 Antigen Test
- Where
- 2 sites in United States
- Volunteers
- 171 people
- Sponsor
- Testing Done Simple
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test
Study will assess sensitivity and specificity of AnavasiDx POC PCR device for detection of Covid-19 in patients presenting for testing a clinical sites.
- Trial name
- NCT04981769
- Testing
- Covid-19 test
- Volunteers
- 1,000 people
- Sponsor
- Anavasi Diagnostics
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral…
- Trial name
- NCT05465902
- Testing
- Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna)
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
The study is a randomized, double-blind, and positive-controlled Phase III booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with either one dose of Sinopharm…
- Trial name
- NCT05323461
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom.
- Trial name
- NCT07090486
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 14,000 people
- Sponsor
- Pfizer
COVID-19
Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China
The purpose of this clinical study, CLO-SCB-2019-010, is to assess the immunogenicity, reactogenicity and safety of the SCB-2019 vaccine in Chinese participants, and to show the comparability of the immune response versus…
- Trial name
- NCT04954131
- Testing
- Candidate Vaccine, SCB-2019
- Where
- 2 sites in China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Zhejiang Clover Biopharmaceuticals, Inc.
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
SARS-CoV2 Infection, COVID-19
IMM-BCP-01 in Mild to Moderate COVID-19
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
- Trial name
- NCT05429021
- Testing
- IMM-BCP-01
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Immunome, Inc.
COVID-19, Rabies
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.
- Trial name
- NCT05453487
- Testing
- coadministration, COVID-19 vaccine, rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.